The pan-HDAC inhibitor SAHA, whichalso acts as a class I and IIb HDAC inhibitor, successfully elevated miR-133alevels in mice that experienced TAC, reducing CTGF, collagen, and fibrosis withinthe myocardium [403]. This evidence concerns the gene HDAC9 and persistent truncus arteriosus.